Intensity Therapeutics, Inc. financial data

Symbol
INTS on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
61 Wilton Road, 3 Rd Floor, Westport, Connecticut
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 598 %
Debt-to-equity 20.1 %
Return On Equity -102 %
Return On Assets -85.3 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.7 M shares
Common Stock, Shares, Outstanding 13.7 M shares
Entity Public Float 22 M USD
Common Stock, Value, Issued 1 K USD
Weighted Average Number of Shares Outstanding, Basic 13.7 M shares +302%
Weighted Average Number of Shares Outstanding, Diluted 13.7 M shares +302%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.83 M USD +264%
General and Administrative Expense 4.98 M USD +302%
Operating Income (Loss) -11.8 M USD -278%
Net Income (Loss) Attributable to Parent -13.8 M USD -245%
Earnings Per Share, Basic -1.33 USD/shares +12.8%
Earnings Per Share, Diluted -1.33 USD/shares +12.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.46 M USD -12.8%
Marketable Securities, Current 8.96 M USD
Cash, Cash Equivalents, and Short-term Investments 10.5 M USD
Other Assets, Current 6 K USD -92.1%
Assets, Current 11.2 M USD
Operating Lease, Right-of-Use Asset 141 K USD
Other Assets, Noncurrent 1.1 M USD
Assets 12.4 M USD
Accounts Payable, Current 1.22 M USD
Employee-related Liabilities, Current 407 K USD +3.83%
Accrued Liabilities, Current 1.27 M USD +43%
Liabilities, Current 2.52 M USD
Operating Lease, Liability, Noncurrent 131 K USD
Other Liabilities, Noncurrent 36 K USD
Liabilities 2.69 M USD
Retained Earnings (Accumulated Deficit) -55.1 M USD
Stockholders' Equity Attributable to Parent 9.72 M USD
Liabilities and Equity 12.4 M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.37 M USD -385%
Net Cash Provided by (Used in) Financing Activities 8 K USD -96.1%
Net Cash Provided by (Used in) Investing Activities 3.26 M USD
Common Stock, Shares Authorized 135 M shares
Common Stock, Shares, Issued 13.7 M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.1 M USD -57.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.46 M USD +1111%
Deferred Tax Assets, Valuation Allowance 12 M USD +18.7%
Deferred Tax Assets, Gross 12 M USD +18.7%
Operating Lease, Liability 157 K USD
Lessee, Operating Lease, Liability, to be Paid 185 K USD
Operating Lease, Liability, Current 26 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 37 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 36 K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 28 K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 39 K USD
Deferred Tax Assets, Operating Loss Carryforwards 8.61 M USD +6.92%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15 M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 39 K USD
Operating Lease, Payments 3 K USD -93.9%
Additional Paid in Capital 64.8 M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 39 K USD +30%
Share-based Payment Arrangement, Expense 2.24 M USD +270%
Interest Expense 0 USD -100%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares